OBJECTIVES: To identify sociodemographic factors associated with off-patent brand antidepressants utilization.  METHODS: Secondary data analysis was conducted using 2010 Medical Expenditure Panel Survey (MEPS). Although the following medications were available in generic products as of 2010: Venlafaxine, Fluoxetine, Paroxetine, Bupropion, Citalopram, Sertraline, Mirtazapine. 216 unique participants were identified as brand users out of 1694 participants taking the aforementioned medications. Race, family’s total income, health insurance coverage, gender, and age were categorized and included first in bivariate logistic regression to identify significant predictor variables for the utilization of off-patent brand antidepressants. Charlson Co-morbidity Index (CCI) score was calculated using ICD9CODX variable and the total score was included in the analysis. The significant predictor variables were then included in multivariable logistic regression model. RESULTS: Brand users were more likely to be White (non-Hispanic) (OR=2.158, 95% CI =1.27-3.659), female (OR=1.678, 95% CI = 1.109-2.537), having private insurance (OR=1.481, 95% CI= 1.028-2.134) and from upper middle income class (family’s total income: $100,000-$500,000) (OR=1.595, 95% CI= 1.030-2.471). However, race (White (non-Hispanic)) and gender (female) variables were found to be significantly associated with brand utilization (P<0.05) after accounting for income and insurance coverage. Participants with zero CCI score (absence of CCI’s 17 chronic medical conditions) were more likely to be brand user (OR=1.286, 95% CI= 0.901-1.837) although this was not found to be statistically significant (P>0.05). CONCLUSIONS: Despite some case reports and bioequivalence studies suggesting a disadvantage in efficacy and tolerability of generic medications compared with brand-name equivalents, the preponderance of evidence suggests that generic antidepressants provide cost savings over brand-name medications and equal discontinuation rate. Racial as well as gender differences in brand antidepressants preferences were identified, which will possibly help clinicians counsel patients with higher likelihood of utilizing off-patent brand-name antidepressants to help dispel any misconceptions about generic antidepressants’ efficacy.